ADOCIA Reports Third Quarter 2026 Financial Results and Provides a Business Update

Olivier Soula, Chief Executive Officer and Co-Founder of Adocia

“With our cash runway now extended into the first quarter of 2028, we have the time needed to receive the BC Lispro milestone payment, subject to marketing approval in China, and to convert the growing interest in BioChaperone(®) into partnerships. In this regard, we are now offering pharmaceutical companies the opportunity to evaluate the technology freely within the framework of a paid R&D collaboration. We are convinced that the ability to use BioChaperone(®) confidentially for strategic purposes is of significant value to pharma companies. This approach, which complements the feasibility studies, will create opportunities that are currently out of reach”

Olivier Soula, Chief Executive Officer and Co-Founder of Adocia

“We are also preparing the ground for the distribution of BC Lispro outside of China and a few other Asian countries, where Adocia retains all rights.”

Mathieu-William Gilbert, CFO-COO of Adocia

“The transaction completed last week, combined with the ongoing reduction in our cash burn allows us to extend our cash runway up to the first quarter of 2028 and beyond subject to approval of BC Lispro in China. We are also being stringent stewards of our resources and have started to reduce costs across the whole organization to focus on activities that could lead to partnering opportunities in the near term.”